GENE THERAPY FOR THE TREATMENT OF CAMT

治疗 CAMT 的基因疗法

• 批准号: 7531193
• 负责人: Neil Josephson
• 金额: $ 48.93万
• 依托单位: BLOODWORKS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7531193
• 关键词: Affect; Allogenic; Autologous; Biological Assay; Blood Cell Count; Blood Cells; Breeding; CD34 gene; Cell Count; Cell Survival; Cells; Clinical Treatment; Clinical Trials; Code; Commit; Condition; Count; Defect; Development; Disease; Doctor of Medicine; Ensure; Evaluation; Flow Cytometry; Gene Expression; Gene Transfer; Generations; Genes; Germ Cells; Germ Lines; Grant; Green Fluorescent Proteins; Growth; Harvest; Hematopoiesis; Hematopoietic; Hematopoietic stem cells; Human; Individual; Inherited; Intercistronic Region; Lymphoid; MPL gene; Marrow; Megakaryocytes; Molecular; Mus; Myelogenous; Numbers; Pancytopenia; Patients; Pattern; Phylogenetic Analysis; Protocols documentation; Reporter; Reporter Genes; Research; Research Personnel; Retroviridae; Safety; Specificity; Spumavirus; Standards of Weights and Measures; Stem cell transplant; Stem cells; System; Techniques; Testing; Thrombocytopenia; Thrombopoietin; Tissue-Specific Gene Expression; Tissues; Transgenes; Transgenic Mice; Transgenic Organisms; Transplant Recipients; Transplantation; Work; base; cellular transduction; expression vector; gene correction; gene therapy; human MPL protein; improved; loss of function mutation; mouse model; peripheral blood; pre-clinical; progenitor; programs; promoter; prototype; restoration; retroviral-mediated; transduction efficiency; transgene expression; vector